Axsome stock jumped Wednesday after the biotech firm said its Alzheimer's disease agitation drug will get a priority review.

Axsome Therapeutics (AXSM) saw its stock surge after the FDA accepted its supplemental New Drug Application (sNDA) for AXS-05 in treating agitation in Alzheimer

Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved for adults with major depressive disorder (MDD).

Pharma stock Axsome Therapeutics Inc (NASDAQ:AXSM) is soaring to all-time highs, up 19% at $177.13 at last glance, after the U.S. Food & Drug Administration (FDA) granted priority review to AXS-05 -- its Alzheimer's disease agitation drug.

On Wednesday, the U.S. Food and Drug Administration (FDA) accepted Axsome Therapeutics Inc.'s (NASDAQ: AXSM) supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl) for Alzheimer's disease agitation.

Oversold shares of Nike (NYSE: NKE) are on the run. All on news that CEO Elliott Hill bought 16,400 shares for about $1 million. This follows news that Apple's Tim Cook bought $3 million worth of Nike stock. Cook, who has been on the NKE board since 2005, bought 50,000 shares at an average price... Market Movers: Nike Exploding Higher on Insider Buying.

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.

New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting an NDA submission for AXS-12 in narcolepsy. AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator.

Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) reached a new 52-week high during trading on Friday. The stock traded as high as $154.49 and last traded at $151.96, with a volume of 183511 shares traded. The stock had previously closed at $147.00. Wall Street Analyst Weigh In AXSM has been the topic of

Assenagon Asset Management S.A. increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 62.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 294,771 shares of the company's stock after purchasing an additional 113,811 shares during the period. Assenagon Asset